Gotowe bibliografie tematyczne / Antiphospholipid syndrome / Artykuły w czasopismach

Artykuły w czasopismach na temat „Antiphospholipid syndrome”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Antiphospholipid syndrome.
Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 9 marca 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Antiphospholipid syndrome”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Dutra, Livia Almeida, Pedro Braga-Neto, José Luiz Pedroso i Orlando Graziani Povoas Barsottini. "Sneddon's syndrome: case report and review of its relationship with antiphospholipid syndrome". Einstein (São Paulo) 10, nr 2 (czerwiec 2012): 230–32. http://dx.doi.org/10.1590/s1679-45082012000200018.

Pełny tekst źródła
Streszczenie:
The Sneddon's syndrome is a rare disorder characterized by the occurrence of cerebrovascular disease associated with livedo reticularis. The antiphospholipid syndrome is the most frequent type of acquired thrombophilia, defined by the occurrence of thrombosis or pregnancy morbidity in the presence of persistently positive antiphospholipid antibodies. Approximately 80% of Sneddon's syndrome patients have an antiphospholipid antibody marker. These antibodies may play a pathogenetic role in some cases of Sneddon's syndrome, and many authors consider these two syndromes as the same entity. Although clinical features of antiphospholipid syndrome and Sneddon's syndrome may overlap, there is a distinction between clinical and laboratory evidence suggesting that these two entities are different diseases. A recent finding of coagulopathies, including elevated levels of coagulation factor VII, decreased levels of protein S, and activated protein C in Sneddon's syndrome patients suggested a possible biological link between the vasculopathy and a primary coagulopathy. Moreover, the clinical course seems to be progressive in Sneddon's syndrome patients and includes increase of disability and cognitive deterioration, more arterial involvement, and the antiphospholipid syndrome shows a more benign course. Both syndromes share clinical and laboratory features, and whether Sneddon's syndrome represents a spectrum of antiphospholipid syndrome remains unclear. Sneddon's syndrome patients have a worse prognosis and may represent a subgroup of patients who demands more rigorous follow-up. It is important to recognize the Sneddon's syndrome, particularly because stroke episodes may be prevented through appropriate treatment.
Style APA, Harvard, Vancouver, ISO itp.
2

Khamashta, Munther A., i Graham R. V. Hughes. "Antiphospholipid antibodies and antiphospholipid syndrome". Current Opinion in Rheumatology 7, nr 5 (wrzesień 1995): 389–94. http://dx.doi.org/10.1097/00002281-199509000-00005.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Pavlovic, Dragan, i Aleksandra Pavlovic. "Antiphospholipid syndrome". Srpski arhiv za celokupno lekarstvo 138, nr 9-10 (2010): 651–57. http://dx.doi.org/10.2298/sarh1010651p.

Pełny tekst źródła
Streszczenie:
Antiphospholipid syndrome (APS) is an autoimmune disease with recurrent thromboses and pregnancy complications (90% are female patients) that can be primary and secondary (with concomitant autoimmune disease). Antiphospholipid antibodies are prothrombotic but also act directly with brain tissue. One clinical and one laboratory criterion is necessary for the diagnosis of APS. Positive serological tests have to be confirmed after at least 12 weeks. Clinical picture consists of thromboses in many organs and spontaneous miscarriages, sometimes thrombocytopaenia and haemolytic anaemia, but neurological cases are the most frequent: headaches, stroke, encephalopathy, seizures, visual disturbances, Sneddon syndrome, dementia, vertigo, chorea, balism, transitory global amnesia, psychosis, transversal myelopathy and Guillain-Barre syndrome. About 50% of strokes below 50 years of age are caused by APS. The first line of therapy in stroke is anticoagulation: intravenous heparin or low-weight heparins. In chronic treatment, oral anticoagulation and antiplatelet therapy are used, warfarin and aspirin, mostly for life. In resistant cases, corticosteroids, intravenous immunoglobulins and plasmapheresis are necessary. Prognosis is good in most patients but some are treatment-resistant with recurrent thrombotic events and eventually death.
Style APA, Harvard, Vancouver, ISO itp.
4

IKEDA, Yasuo. "Antiphospholipid Syndrome". Japanese Journal of Thrombosis and Hemostasis 2, nr 2 (1991): 112–21. http://dx.doi.org/10.2491/jjsth.2.112.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

ABE, Nobuya, i Tatsuya ATSUMI. "Antiphospholipid syndrome". Japanese Journal of Thrombosis and Hemostasis 29, nr 3 (2018): 294–306. http://dx.doi.org/10.2491/jjsth.29.294.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Santos, Thaís da Silva, Izabel Galhardo Demarchi, Tatiane França Perles Mello, Jorge Juarez Vieira Teixeira i Maria Valdrinez Campana Lonardoni. "Antiphospholipid Syndrome". REVISTA CIÊNCIAS EM SAÚDE 9, nr 4 (25.11.2019): 37–42. http://dx.doi.org/10.21876/rcshci.v9i4.892.

Pełny tekst źródła
Streszczenie:
Antiphospholipid syndrome (APS) was characterized as an autoimmune condition with the production of antiphospholipid antibodies (aPL) associated with thrombosis and morbidity in pregnancy. The prevalence of aPL in the population ranges from 1% to 5% in patients with APS. The hypotheses regarding pathophysiological mechanisms are strongly related to binding proteins and antiphospholipid antibodies. The exact mechanisms by which they lead to clinical manifestations appear to be heterogeneous, but it is believed which aPL contribute to the cellular activation/coagulation, and so cause the thrombotic events. The treatment of APS should be an individual character and several factors should be taken into accounts, such as a number of antibodies, the age of the patient and the history of thrombotic events.
Style APA, Harvard, Vancouver, ISO itp.
7

ICHIKAWA, Kenji, Akito TSUTSUMI, Eiji MATSUURA i Takao KOIKE. "Antiphospholipid Syndrome." Internal Medicine 38, nr 2 (1999): 170–73. http://dx.doi.org/10.2169/internalmedicine.38.170.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Makarenko, E. V. "ANTIPHOSPHOLIPID SYNDROME". Health and Ecology Issues, nr 4 (28.12.2017): 4–11. http://dx.doi.org/10.51523/2708-6011.2017-14-4-1.

Pełny tekst źródła
Streszczenie:
Antiphospholipid syndrome is autoimmune acquired thrombophilia associated with the formation of antibodies to phospholipids, which is manifested by recurrent venous or arterial thrombosis and/or pathology of pregnancy. Antiphospholipid antibodies are a heterogeneous group of autoantibodies interacting with phospholipids, which are components of cell membranes and phospholipid-binding proteins of blood plasma. Antiphospholipid syndrome can affect vessels of any caliber and localization, with thrombosis accompanied by no morphological signs of inflammation in the wall of the vessel. Obstetrical pathology is manifested by loss of the fetus, which can occur at any time of pregnancy, as well as other complications of pregnancy, such as preeclampsia and placental insufficiency. Based on the classification criteria, antiphospholipid syndrome is diagnosed if one of the clinical criteria (thrombosis or pregnancy complication) and one of the laboratory criteria including the lupus anticoagulant, antibodies to cardiolipin or β2-glycoprotein I, are revealed. The main tactic of the treatment of patients with antiphospholipid syndrome is to prevent thrombosis. For this purpose, the traditional therapy with anticoagulants and antiaggregants is applied. In addition, new medicines are being developed and evaluated
Style APA, Harvard, Vancouver, ISO itp.
9

Koike, Takao. "Antiphospholipid syndrome." Ensho 20, nr 5 (2000): 571–80. http://dx.doi.org/10.2492/jsir1981.20.571.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Arnout, Jef, i Milosz Jankowski. "Antiphospholipid syndrome". Hematology Journal 5 (2004): S1—S5. http://dx.doi.org/10.1038/sj.thj.6200412.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
11

Jallow, T., D. D'Cruz i H. Lempp. "Antiphospholipid syndrome". BMJ 350, apr02 3 (2.04.2015): h1426. http://dx.doi.org/10.1136/bmj.h1426.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
12

Greaves, M. "Antiphospholipid syndrome." Journal of Clinical Pathology 50, nr 12 (1.12.1997): 973–74. http://dx.doi.org/10.1136/jcp.50.12.973.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
13

Zuo, Yu, Hui Shi, Chun Li i Jason S. Knight. "Antiphospholipid syndrome". Chinese Medical Journal 133, nr 8 (kwiecień 2020): 929–40. http://dx.doi.org/10.1097/cm9.0000000000000705.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
14

Espinosa, Gerard, i Ricard Cervera. "Antiphospholipid syndrome". Arthritis Research & Therapy 10, nr 6 (2008): 230. http://dx.doi.org/10.1186/ar2536.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
15

Asherson, Ronald A., i Ricard Cervera. "Antiphospholipid Syndrome." Journal of Investigative Dermatology 100, nr 1 (styczeń 1993): 21S—27S. http://dx.doi.org/10.1111/1523-1747.ep12355193.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
16

Nash, Michael J., i Hannah Cohen. "Antiphospholipid Syndrome". Medicine 30, nr 10 (październik 2002): 31–32. http://dx.doi.org/10.1383/medc.30.10.31.28251.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
17

Austin, Steven, i Hannah Cohen. "Antiphospholipid syndrome". Medicine 34, nr 11 (listopad 2006): 472–75. http://dx.doi.org/10.1053/j.mpmed.2006.08.012.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
18

Alhasson, Hussam, Abdullah Abdullah, Amr Salama, Richard Alweis i Timothy Woodlock. "Antiphospholipid Syndrome". American Journal of Therapeutics 27, nr 3 (2020): e328-e330. http://dx.doi.org/10.1097/mjt.0000000000000995.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
19

van Os, G. M. A., R. T. Urbanus, C. Agar, J. C. M. Meijers i P. G. de Groot. "Antiphospholipid syndrome". Hämostaseologie 30, nr 03 (2010): 139–43. http://dx.doi.org/10.1055/s-0037-1619044.

Pełny tekst źródła
Streszczenie:
SummaryThe antiphospholipid syndrome (APS) is a non-inflammatory autoimmune disease characterized by the presence of antiphospholipid antibodies (aPL) in the plasma of patients with vascular thrombosis, recurrent complications of pregnancy, or both (1, 2). The presence of aPL in plasma of patients can be detected with either a prolongation of phospholipid dependent coagulation tests (lupus anticoagulant, LAC), or with solid phase immune assays against the protein β2-glycoprotein I (β2-GPI) or the phospholipid cardiolipin (anti-β2-GPI antibody ELISA and anti-cardiolipin antibody ELISA, respectively) (3). For a long time there was a lot of confusion on who had the syndrome and who not. To solve this dispute, an international consensus meeting was organized in Sapporo in 1999 to formulate classification criteria for patients with the antiphospholipid syndrome (4). These criteria have been updated in 2004 at another international consensus meeting in Sydney (5). The classification criteria were defined for scientific purposes and were aimed to be used as inclusion criteria in patient related studies. They were specifically not defined for diagnostic purposes. However, current practice is that these criteria are used as a diagnostic tool. This is very unfortunate because the specificity of the different aPL assays to detect the clinical manifestations that characterize APS are disputable. One of the aims of defining the criteria was to initiate studies to determine the value of the different anti-phospholipid antibody assays to serve as biomarker for the risk of thrombosis and pregnancy morbidity. The recent progress made on this important topic will be discussed.
Style APA, Harvard, Vancouver, ISO itp.
20

Danowski, Adriana, i Roger A. Levy. "Antiphospholipid syndrome". Revista Brasileira de Reumatologia (English Edition) 53, nr 2 (marzec 2013): 139–40. http://dx.doi.org/10.1016/s2255-5021(13)70018-x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
21

Cervera, Ricard. "Antiphospholipid syndrome". Thrombosis Research 151 (marzec 2017): S43—S47. http://dx.doi.org/10.1016/s0049-3848(17)30066-x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
22

Ruiz-Irastorza, Guillermo, Mark Crowther, Ware Branch i Munther A. Khamashta. "Antiphospholipid syndrome". Lancet 376, nr 9751 (październik 2010): 1498–509. http://dx.doi.org/10.1016/s0140-6736(10)60709-x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
23

Austin, Steven, i Hannah Cohen. "Antiphospholipid syndrome". Medicine 38, nr 2 (luty 2010): 101–4. http://dx.doi.org/10.1016/j.mpmed.2009.10.012.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
24

Jayakody Arachchillage, Deepa, i Hannah Cohen. "Antiphospholipid syndrome". Medicine 42, nr 3 (marzec 2014): 156–61. http://dx.doi.org/10.1016/j.mpmed.2013.12.001.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
25

Clark, Kristina E. N., i Ian Giles. "Antiphospholipid syndrome". Medicine 46, nr 2 (luty 2018): 118–25. http://dx.doi.org/10.1016/j.mpmed.2017.11.006.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
26

Petri, Michelle. "Antiphospholipid syndrome". Translational Research 225 (listopad 2020): 70–81. http://dx.doi.org/10.1016/j.trsl.2020.04.006.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
27

Ravelli, Angelo, i Alberto Martini. "Antiphospholipid Syndrome". Pediatric Clinics of North America 52, nr 2 (kwiecień 2005): 469–91. http://dx.doi.org/10.1016/j.pcl.2005.01.001.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
28

Branch, D. Ware, i Munther A. Khamashta. "Antiphospholipid Syndrome". Obstetrics & Gynecology 101, nr 6 (czerwiec 2003): 1333–44. http://dx.doi.org/10.1097/00006250-200306000-00031.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
29

Damron, Dana P. "Antiphospholipid Syndrome". Obstetrics & Gynecology 102, nr 4 (październik 2003): 873. http://dx.doi.org/10.1097/00006250-200310000-00040.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
30

Branch, Ware. "Antiphospholipid Syndrome". Obstetrics & Gynecology 102, nr 4 (październik 2003): 873. http://dx.doi.org/10.1097/00006250-200310000-00041.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
31

Gromnica-Ihle, Erika, i W. Schössler. "Antiphospholipid Syndrome". International Archives of Allergy and Immunology 123, nr 1 (2000): 67–76. http://dx.doi.org/10.1159/000024425.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
32

Keswani, Sanjay C., i Naresh Chauhan. "Antiphospholipid Syndrome". Journal of the Royal Society of Medicine 95, nr 7 (lipiec 2002): 336–42. http://dx.doi.org/10.1177/014107680209500705.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
33

George, Diane, i Doruk Erkan. "Antiphospholipid Syndrome". Progress in Cardiovascular Diseases 52, nr 2 (wrzesień 2009): 115–25. http://dx.doi.org/10.1016/j.pcad.2009.06.005.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
34

Nelson, Gregory N. "Antiphospholipid Syndrome". Journal of Hand Surgery 35, nr 11 (listopad 2010): 1890–92. http://dx.doi.org/10.1016/j.jhsa.2010.07.003.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
35

Manson, J. J., i D. A. Isenberg. "Antiphospholipid syndrome". International Journal of Biochemistry & Cell Biology 35, nr 7 (lipiec 2003): 1015–20. http://dx.doi.org/10.1016/s1357-2725(02)00313-8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
36

Corban, Michel T., Ali Duarte-Garcia, Robert D. McBane, Eric L. Matteson, Lilach O. Lerman i Amir Lerman. "Antiphospholipid Syndrome". Journal of the American College of Cardiology 69, nr 18 (maj 2017): 2317–30. http://dx.doi.org/10.1016/j.jacc.2017.02.058.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
37

Gezer, Sefer. "Antiphospholipid syndrome". Disease-a-Month 49, nr 12 (grudzień 2003): 696–741. http://dx.doi.org/10.1016/j.disamonth.2003.10.001.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
38

Khamashta, M., i G. R. Hughes. "Antiphospholipid syndrome." BMJ 307, nr 6909 (9.10.1993): 883–84. http://dx.doi.org/10.1136/bmj.307.6909.883.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
39

Martinez, Alan P., i Mark T. Cunningham. "Antiphospholipid syndrome". Blood Coagulation & Fibrinolysis 27, nr 5 (lipiec 2016): 557–62. http://dx.doi.org/10.1097/mbc.0000000000000550.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
40

Annem, Chandrahasa, i Richard A. Furie. "Antiphospholipid Syndrome". JCR: Journal of Clinical Rheumatology 23, nr 5 (sierpień 2017): 278–84. http://dx.doi.org/10.1097/rhu.0000000000000564.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
41

&NA;. "Antiphospholipid Syndrome". Obstetric Anesthesia Digest 26, nr 2 (czerwiec 2006): 52–53. http://dx.doi.org/10.1097/00132582-200606000-00008.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
42

Asherson, Ronald A., i Ricard Cervera. "Antiphospholipid Syndrome". Journal of Investigative Dermatology 100, nr 1 (1993): S21—S27. http://dx.doi.org/10.1038/jid.1993.19.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
43

Lim, Wendy. "Antiphospholipid syndrome". Hematology 2013, nr 1 (6.12.2013): 675–80. http://dx.doi.org/10.1182/asheducation-2013.1.675.

Pełny tekst źródła
Streszczenie:
Abstract The antiphospholipid syndrome (APS) is defined by venous or arterial thrombosis and/or pregnancy morbidity in patients with persistent presence of antiphospholipid antibodies (aPLs). Catastrophic APS is the most severe form of APS, which is associated with rapid development of microvascular thrombosis resulting in multiorgan failure in patients with aPLs. Patients with APS and catastrophic APS are recognized to have a high risk of recurrent thrombosis that can occur despite anticoagulant therapy. Although antithrombotic therapy remains the mainstay of treatment, bleeding manifestations can complicate management and contribute to increased morbidity. Patients with persistently elevated aPL levels, particularly those who exhibit positive testing for lupus anticoagulant, anticardiolipin antibodies, and anti-β2GPI antibodies (triple positivity), appear to be at increased risk for thrombosis and pregnancy complications, whereas isolated positivity for aPLs appears to be associated with low risk. Recognizing that patients with APS have different thrombotic risk profiles may assist clinicians in assessing the risks and benefits of anticoagulation. The optimal type, intensity, and duration of anticoagulation in the treatment of APS remain controversial, particularly for arterial thrombosis and recurrent thrombosis. Future studies that delineate thrombotic risk in APS and evaluate current and novel anticoagulants as well as nonanticoagulant therapies are required.
Style APA, Harvard, Vancouver, ISO itp.
44

Keswani, S. C., i N. Chauhan. "Antiphospholipid syndrome". JRSM 95, nr 7 (1.07.2002): 336–42. http://dx.doi.org/10.1258/jrsm.95.7.336.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
45

Erkan, Doruk, i Michael D. Lockshin. "Antiphospholipid syndrome". Current Opinion in Internal Medicine 5, nr 4 (sierpień 2006): 378–84. http://dx.doi.org/10.1097/01.bor.0000218943.89365.13.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
46

Lau, CS. "Antiphospholipid Syndrome". Vascular Medicine Review vmr-5, nr 1 (luty 1994): 33–45. http://dx.doi.org/10.1177/1358863x9400500104.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
47

Vreede, Andrew P., Paula L. Bockenstedt i Jason S. Knight. "Antiphospholipid syndrome". Current Opinion in Rheumatology 29, nr 5 (wrzesień 2017): 458–66. http://dx.doi.org/10.1097/bor.0000000000000410.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
48

Khamashta, M., M. Taraborelli, S. Sciascia i A. Tincani. "Antiphospholipid syndrome". Best Practice & Research Clinical Rheumatology 30, nr 1 (luty 2016): 133–48. http://dx.doi.org/10.1016/j.berh.2016.04.002.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
49

Sammaritano, Lisa R. "Antiphospholipid syndrome". Best Practice & Research Clinical Rheumatology 34, nr 1 (luty 2020): 101463. http://dx.doi.org/10.1016/j.berh.2019.101463.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
50

Cuadrado, M. J., i C. Lopez-Pedrera. "Antiphospholipid syndrome". Clinical and Experimental Medicine 3, nr 3 (listopad 2003): 129–39. http://dx.doi.org/10.1007/s10238-003-0016-x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany bibliografiami na temat „Antiphospholipid syndrome” dla innych typów źródeł:
Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii